Wird geladen...
Highly efficient, In-vivo Fas-mediated Apoptosis of B-cell Lymphoma by Hexameric CTLA4-FasL
Non-Hodgkin lymphomas (NHLs) account for 4% of all malignancies. 5-year survival rate increased to 50% with new treatment modalities, however there is need for new effective treatment for the more aggressive, relapsing forms. Recently, CTLA4-FasL, that can bind to B7 and Fas receptor (Fas), was show...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprache: | Inglês |
Veröffentlicht: |
BioMed Central
2014
|
Schlagworte: | |
Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4189725/ https://ncbi.nlm.nih.gov/pubmed/25227919 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-014-0064-6 |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|